Skip to main content
. 2023 Jul 17;39(6):e00232522. doi: 10.1590/0102-311XEN232522

Table 3. Univariate and multiple analysis of factors associated with pregnancy incidence. Rio de Janeiro, Brazil, 1996-2016.

Women characteristics Univariate analysis Multiple analysis *
HR (95%CI) p-value HR (95%CI) p-value
Follow-up period
1996-2000 1.00
2001-2005 0.79 (0.49; 1.28) 0.34 1.17 (0.68; 2.00) 0.57
2006-2010 0.58 (0.37; 0.91) 0.02 0.74 (0.40; 1.37) 0.34
2011-2016 0.59 (0.37; 0.94) 0.03 0.55 (0.29; 1.07) 0.08
Age (years)
< 20 1.00
20-34 0.45 (0.2; 1.0) 0.05 0.63 (0.27; 1.50) 0.30
≥ 35 0.12 (0.05; 0.28) < 0.01 0.22 (0.08; 0.56) < 0.01
Race/Ethnicity
White 1.00
Black 0.94 (0.62; 1.44) 0.79
Mixed 0.72 (0.50; 1.03) 0.07
Missing 0.95 (0.22; 4.16) 0.95
Schooling years
≤ 8 1.00
> 8 0.92 (0.66; 1.27) 0.60
Missing 0.98 (0.13; 7.18) 0.98
Smoking
No 1.00
Yes 1.05 (0.72; 1.53) 0.80
Alcohol use
No 1.00
Yes 0.96 (0.70; 1.31) 0.79
Missing 0.96 (0.21; 4.45) 0.96
Drug use
No 1.00
Yes 1.35 (0.86; 2.13) 0.19
Missing 0.74 (0.20; 2.72) 0.65
Domestic violence
No 1.00
Yes 0.83 (0.58; 1.19) 0.32
Missing 0.33 (0.04; 2.54) 0.28
Sexual violence
No 1.00
Yes 1.13 (0.73; 1.75) 0.57
Missing 1.21 (0.27; 5.42) 0.81
Pregnancy in adolescence
No 1.00 1.00
Yes 1.73 (1.17; 2.56) 0.01 1.65 (1.12; 2.44) 0.01
Missing 1.1 (0.53; 2.30) 0.80 0.57 (0.25; 1.28) 0.17
Age at first sexual intercourse (years)
< 15 1.00
15-19 0.65 (0.45; 0.92) 0.02
≥ 20 0.14 (0.06; 0.30) < 0.01
Missing 0.4 (0.14; 1.20) 0.10
Marital status
Does not live with a partner 1.00
Live with a partner 1.55 (1.12; 2.14) 0.01
Number of children
Median (IQR) 0.83 (0.68; 1.03) 0.09
0 1.00
1 0.64 (0.41; 1.02) 0.06 0.55 (0.36; 0.84) 0.01
≥ 2 0.48 (0.27; 0.83) 0.01 0.43 (0.26; 0.71) < 0.01
Contraceptive method
Low efficacy ** 1.00 1.00
Hormonal or IUD 0.24 (0.08; 0.72) 0.01 0.27 (0.10; 0.78) 0.02
Dual (hormonal or IDU + barrier) 0.53 (0.37; 0.76) < 0.01 0.63 (0.41; 0.99) 0.04
Missing 0.54 (0.33; 0.86) 0.01 0.62 (0.38; 1.02) 0.06
Time since HIV infection diagnosis (years)
< 2 1.00
2-4 1.09 (0.71; 1.66) 0.70
≥ 5 0.94 (0.57; 1.56) 0.81
Missing 3.02 (1.61; 5.66) < 0.01
Diagnosis of opportunistic disease
No 1.00
Yes 0.85 (0.58; 1.24) 0.40
HIV-1 RNA (copies/mL)
< 50 1.00 1.00
≥ 50 0.91 (0.67; 1.24) 0.55 0.57 (0.39; 0.85) 0.01
Missing 2.01 (0.87; 4.67) 0.10 0.91 (0.33; 2.55) 0.86
CD4+ T lymphocyte count nadir (cells/mm³)
Median (IQR) 1.01 (1.01; 1.02) < 0.01
< 200 1.00 1.00
200-349 1.3 (0.90; 1.88) 0.17 1.19 (0.82; 1.73) 0.36
350-499 1.84 (1.17; 2.90) 0.01 2.58 (1.58; 4.23) < 0.01
≥ 500 2 (1.18; 3.38) 0.01 2.78 (1.57; 4.90) < 0.01
ARV use
No use 1.00 1.00
HAART with Efavirenz 0.13 (0.05; 0.34) < 0.01 0.19 (0.07; 0.51) < 0.01
HAART without Efavirenz 2.18 (1.36; 3.51) < 0.01 3.39 (2.01; 5.73) < 0.01
No HAART 2.1 (1.12; 3.91) 0.02 1.69 (0.78; 3.67) 0.19

95%CI: 95% confidence interval; ART: antiretroviral; HAART: highly active antiretroviral therapy; HR: harzard ratio.

* Variables that showed statistical significance in the univariate analysis (p < 0.10) and those clinically relevant were included in the multiple analyses. After backwards selection, variables that were statistically significant at the 5% level were included in the final model;

** Natural, male condom, female condom, diaphragm, withdrawal.